Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could make pituitary tumor imaging more accessible

NCT ID NCT06584123

Diagnosis Sponsor: University of Cambridge Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study at the University of Cambridge is testing whether a new PET scan tracer called FET can locate pituitary tumors as well as the standard tracer, methionine. The study involves 20 adults with suspected pituitary adenomas who have already had a methionine PET scan. If FET works similarly, it could be easier to produce and distribute, potentially expanding access to this type of imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-fluoro-ethyl-tyrosine (FET) PET tracer
What this could lead to
If FET works as well as the current tracer, it could make advanced pituitary tumor imaging more widely available, since FET is easier to produce and distribute.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is also testing a diagnostic tool, not a treatment, so it won't directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Participant is willing and able to give informed consent for participation in the study * Male or female, age 18 or above * Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings * Previous 11C-Met-PET/CT Exclusion criteria * Inability to give informed consent * Pregnancy or suspected pregnancy * Inability to lie supine for 30-60 minutes * Patient body habitus above scanner dimensions * Known allergy to intravenous radiographic contrast agents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pituitary adenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pituitary gland adenoma Pituitary Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pituitary adenoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cambridge University Hospitals

    RECRUITING

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.